{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T19:48:40Z","timestamp":1782935320357,"version":"3.54.5"},"reference-count":55,"publisher":"Informa UK Limited","issue":"7","license":[{"start":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T00:00:00Z","timestamp":1782604800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"funder":[{"name":"external funding sourc"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Therapeutic Patents"],"published-print":{"date-parts":[[2026,7,3]]},"DOI":"10.1080\/13543776.2026.2682837","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T02:49:03Z","timestamp":1782182943000},"page":"593-625","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Takeda G-protein-coupled receptor 5 and farnesoid X receptor agonists for diabetes treatment: a patent review and clinical advancements (2015-present)"],"prefix":"10.1080","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-3903-2048","authenticated-orcid":false,"given":"Shivank","family":"Sharma","sequence":"first","affiliation":[{"name":"Lovely Professional University","place":["Phagwara, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9009-1561","authenticated-orcid":false,"given":"Vanktesh","family":"Kumar","sequence":"additional","affiliation":[{"name":"Lovely Professional University","place":["Phagwara, India"]},{"name":"Ummeed Institute of Pharmaceutical Sciences & Research Center","place":["Sri Ganganagar, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8407-4693","authenticated-orcid":false,"given":"Shubham","family":"Kumar","sequence":"additional","affiliation":[{"name":"Lovely Professional University","place":["Phagwara, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3885-2749","authenticated-orcid":false,"given":"Pankaj","family":"Wadhwa","sequence":"additional","affiliation":[{"name":"Ummeed Institute of Pharmaceutical Sciences & Research Center","place":["Sri Ganganagar, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,6,28]]},"reference":[{"issue":"2","key":"e_1_3_4_2_1","first-page":"232","article-title":"A review on diabetes mellitus-an annihilatory metabolic disorder","volume":"12","author":"Nagesh MR","year":"2020","unstructured":"Nagesh MR, Vijayakumar N, Bhavani K. A review on diabetes mellitus-an annihilatory metabolic disorder. J Pharm Sci Res. 2020;12(2):232\u2013235.","journal-title":"J Pharm Sci Res"},{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1149239"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-020-05215-3"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.32734\/sumej.v7i2.15998"},{"key":"e_1_3_4_6_1","unstructured":"International Diabetes Federation (IDF). IDF diabetes Atlas 11th edition. Brussels Belgium: International Diabetes Federation; 2025. Available from: https:\/\/diabetesatlas.org"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202100275"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14133220"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/9781119785033.ch3"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1021\/acsomega.3c07149"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-981-19-0932-0_12"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1080\/17568919.2025.2463869"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.2174\/1573399817666210917122745"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2023.09.006"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-018-0824-8"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.3390\/nu14224801"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13098-023-00983-5"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-57983-4"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.15212\/bioi-2024-0137"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.obmed.2021.100329"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.37349\/eemd.2025.101428"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-57241-7"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40001-025-02682-5"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2025.105734"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.3390\/molecules28155870"},{"key":"e_1_3_4_26_1","unstructured":"Ashik T. Identifying alterations in adipose tissue-derived islet GPCR peptide ligand mRNAs in obesity: implications for islet function: [Ph. D.thesis]. London United Kingdom: King\u2019s College London; 2023."},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.2337\/db18-0315"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1089\/ars.2024.0799"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41589-020-0604-z"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.15698\/cst2021.01.239"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232213967"},{"key":"e_1_3_4_32_1","volume-title":"Chemical biology studies on human and mouse secondary bile acids","author":"Lu Y","year":"2022","unstructured":"Lu Y, Gilmer JF. Chemical biology studies on human and mouse secondary bile acids. Dublin, Ireland: Trinity College Dublin; 2022."},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.772435"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1515\/mr-2024-0020"},{"key":"e_1_3_4_35_1","volume-title":"Relevance of oxysterol 7-alpha-hydroxylase (CYP7B1) for lipid metabolism and fatty liver disease","author":"Evangelakos I","year":"2022","unstructured":"Evangelakos I. Relevance of oxysterol 7-alpha-hydroxylase (CYP7B1) for lipid metabolism and fatty liver disease. Hamburg, Germany: Staats-und Universit\u00e4tsbibliothek Hamburg Carl von Ossietzky; 2022."},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.3390\/nu14234950"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543776.2012.733000"},{"key":"e_1_3_4_38_1","unstructured":"Zhang X Wall M Sui Z. Tetrahydro-benzoimidazolyl modulators of TGR5 (international patent application publication No. WO 2015\/160772 A1). World Intellectual Property Organization; 2015. Available from: https:\/\/patents.google.com\/patent\/WO2015160772A1\/en"},{"key":"e_1_3_4_39_1","unstructured":"Intercept Pharmaceuticals Inc. TGR5 modulators and methods of use thereof. U.S. Patent No. 9 243 027 B2. U.S. Patent and Trademark Office; Available from: https:\/\/patents.google.com\/patent\/US9243027B2\/en"},{"key":"e_1_3_4_40_1","unstructured":"Bar Pharmaceuticals SRL. 2-oxo-3 4-dihydropyridine-5-carboxylates and their use. U.S. Patent application publication No. US 2017\/0190731. U.S. Patent and Trademark Office A1. Available from: https:\/\/patents.google.com\/patent\/US20170190731A1\/en"},{"key":"e_1_3_4_41_1","unstructured":"Ardelyx Inc. Substituted 4-phenyl pyridine compounds as non-systemic TGR5 agonists. U.S. Patent application publication No. 2017\/0174718. U.S. Patent and Trademark Office A1. Available from: https:\/\/patents.google.com\/patent\/US20170174718A1\/en"},{"key":"e_1_3_4_42_1","unstructured":"Universite de Lille 2 Droit et Sante; Institut Pasteur de Lille; INSERM. 2-oxo-3 4-dihydropyridine-5-carboxylates and their use (U.S. Patent No. 9 932 309 B2). U.S. Patent and Trademark Office; Available from: https:\/\/patents.google.com\/patent\/US9932309B2\/en"},{"key":"e_1_3_4_43_1","unstructured":"Universite de Lille 2 Droit et Sante; Institut Pasteur de Lille; INSERM. Imidazol- or 1 2 4-triazol-derivatives and their use. U.S. Patent No. 10 323 016 B2. U.S. Patent and Trademark Office; Available from: https:\/\/patents.google.com\/patent\/US10323016B2\/en"},{"key":"e_1_3_4_44_1","unstructured":"Enanta Pharmaceuticals Inc. Benzoic acid derivatives of bile acid as FXR\/TGR5 agonists and methods of use thereof (U.S. Patent No. 10 323 060 B2). U.S. Patent and Trademark Office; Available from: https:\/\/patents.google.com\/patent\/US10323060B2\/en"},{"key":"e_1_3_4_45_1","unstructured":"Enanta Pharmaceuticals Inc. Bile acid derivatives as FXR\/TGR5 agonists and methods of use thereof (U.S. Patent No. 10 208 081 B2). U.S. Patent and Trademark Office; Available from: https:\/\/patents.google.com\/patent\/US10208081B2\/en"},{"key":"e_1_3_4_46_1","unstructured":"Enanta Pharmaceuticals Inc. Heteroaryl containing bile acid analogs as FXR\/TGR5 agonists and methods of use thereof (U.S. Patent No. 10 323 061 B2). U.S. Patent and Trademark Office; Available from: https:\/\/patents.google.com\/patent\/US10323061B2\/en"},{"key":"e_1_3_4_47_1","unstructured":"Enanta Pharmaceuticals Inc. Process for preparation of sulfonylurea bile acid derivatives (U.S. Patent No. 10 584 145 B2). U.S. Patent and Trademark Office; Available from: https:\/\/patents.google.com\/patent\/US10584145B2\/en"},{"key":"e_1_3_4_48_1","unstructured":"Enanta Pharmaceuticals Inc. Process for preparation of sulfonyl carbamate bile acid derivatives (U.S. Patent No. 10 676 500 B2). U.S. Patent and Trademark Office; Available from: https:\/\/patents.google.com\/patent\/US10676500B2\/en"},{"key":"e_1_3_4_49_1","unstructured":"Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds (U.S. Patent No. 10 662 171 B2). U.S. Patent and Trademark Office; Available from: https:\/\/patents.google.com\/patent\/US10662171B2\/en"},{"key":"e_1_3_4_50_1","unstructured":"Intercept Pharmaceuticals Inc. TGR5 modulators and methods of use thereof (U.S. Patent application publication No. 2021\/0269473). U.S. Patent and Trademark Office p. A1. Available from: https:\/\/patents.google.com\/patent\/US20210269473A1\/en"},{"key":"e_1_3_4_51_1","unstructured":"Enanta Pharmaceuticals Inc. Bile acid derivatives as FXR\/TGR5 agonists and methods of use thereof (U.S. Patent application publication No. 2024\/0327452 A1). U.S. Patent and Trademark Office; Available from: https:\/\/patents.google.com\/patent\/US20240327452A1\/en"},{"key":"e_1_3_4_52_1","unstructured":"Enanta Pharmaceuticals Inc. Bile acid derivatives as FXR\/TGR5 agonists and methods of use thereof (U.S. Patent No. 12 281 140 B2). U.S. Patent and Trademark Office; 2025. Available from: https:\/\/patents.google.com\/patent\/US12281140B2\/en"},{"key":"e_1_3_4_53_1","unstructured":"Ardelyx Inc. Hormone receptor modulators for treating metabolic conditions and disorders (U.S. Patent application No. US 2025\/0115608). U.S. Patent and Trademark Office p. A1. Available from: https:\/\/patents.google.com\/patent\/US20250115608A1\/en"},{"key":"e_1_3_4_54_1","unstructured":"Ardelyx Inc. Substituted 4-phenyl pyridine compounds as non-systemic TGR5 agonists (U.S. Patent application No. US 2025\/0066410). U.S. Patent and Trademark Office p. A1. Available from: https:\/\/patents.google.com\/patent\/US20250066410A1\/en"},{"key":"e_1_3_4_55_1","unstructured":"Ardelyx Inc. Hormone receptor modulators for treating metabolic conditions and disorders (U.S. Patent No. 12 209 088 B2). U.S. Patent and Trademark Office; 2025 Jan 28. Available from: https:\/\/patents.google.com\/patent\/US12209088B2\/en"},{"key":"e_1_3_4_56_1","unstructured":"Amryt Pharma DAC. Methods of treating hyperphosphatemia using polymeric binders (U.S. Patent No. 12 186 329 B2). U.S. Patent and Trademark Office; Available from: https:\/\/patents.google.com\/patent\/US12186329B2\/en"}],"container-title":["Expert Opinion on Therapeutic Patents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543776.2026.2682837","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/13543776.2026.2682837","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543776.2026.2682837","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T18:06:24Z","timestamp":1782929184000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13543776.2026.2682837"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,28]]},"references-count":55,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7,3]]}},"alternative-id":["10.1080\/13543776.2026.2682837"],"URL":"https:\/\/doi.org\/10.1080\/13543776.2026.2682837","relation":{},"ISSN":["1354-3776","1744-7674"],"issn-type":[{"value":"1354-3776","type":"print"},{"value":"1744-7674","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,28]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ietp20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ietp20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-12-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-28","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}